Breaking AI & Tech News Analyzed

Matthew Macfadyen headlines the new Sky Atlantic series ‘The Miniature Wife’, playing scientist Les Littlejohn, a brilliant but ethically dubious researcher who accidentally shrinks his wife Lindy (Elizabeth Banks) to six inches tall. The premise promises a darkly comic exploration of marital power dynamics and modern misogyny. However, the show quickly abandons this fertile ground. Showrunners Jennifer Ames and Steve Turner opt for a frenetic, screwball tone that feels forced, leaving the underlying commentary underdeveloped. The central conceit – a miniature wife trapped in a dollhouse – is treated more as a visual gag than a vehicle for satire. The series is littered with side plots that never coalesce. A subplot about a misattributed short story attempts to touch on authorship and truth in the digital age, yet it remains a superficial gesture. Likewise, the ensemble cast—including Zoe Lister‑Jones as a lab overseer, O‑T Fagbenle as a lovelorn colleague, and Sian Clifford as Lindy’s agent—offers colorful moments but fails to achieve narrative momentum. Visually, the production delivers inventive set pieces: Lindy’s daring escapes from towering household objects and explosive laboratory experiments provide occasional laughs. Nevertheless, the novelty wears thin before the series’ nearly ten‑hour runtime concludes. The original short story by Manuel Gonzales required far more expansion than the show supplies, resulting in a stretched‑out narrative that would have benefited from a tighter format. In short, while Macfadyen’s performance is competent, it is largely wasted in a series that promises depth but delivers only scattered comedy. ‘The Miniature Wife’ may satisfy viewers seeking light‑hearted antics, but it falls short of the incisive satire its premise suggests. The series is available on Sky Atlantic, streaming on Now in the UK and on Stan in Australia.

Oil markets experienced a dramatic correction on Wednesday, with Brent crude falling 13.9% to $94.10 per barrel and U.S. WTI futures sliding almost 16% to $95, marking the steepest daily percentage drop since the COVID‑19 crash of April 2020. Despite the plunge, prices remain well above pre‑conflict levels, when Brent traded below $73.The price shock followed President Donald Trump's announcement of a two‑week, conditional ceasefire with Iran, contingent on Tehran reopening the strategic Strait of Hormuz for oil tankers. Iran’s foreign minister, Abbas Araghchi, confirmed the strait would be managed by the Iranian military during the grace period, while Iran’s national security council accepted the ceasefire on the condition that U.S. attacks be halted.Equity markets reacted positively. The pan‑European Stoxx 600 surged 4%, its biggest one‑day gain in over four years. In the UK, the FTSE 100 climbed nearly 3% to 10,646 points, its highest level since the early days of the Iran war. Travel and leisure stocks led the rally, with Air France up 14.5%, Lufthansa +11%, IAG +9.5% and TUI +12%.Oil majors were the notable laggards; BP and Shell each lost more than 5% as investors priced in continued supply uncertainty. Asian markets also posted strong gains: Japan’s Nikkei 225 rose over 5%, Australia’s S&P;/ASX 200 jumped 2.55%, South Korea’s Kospi surged 7.5%, Hong Kong’s Hang Seng added 3.1% and China’s CSI300 climbed 3.2%.Bond yields eased on the ceasefire news. The U.S. 10‑year Treasury yield fell to 4.24% from 4.30%, while the UK 10‑year gilt slipped to 4.7% from 4.9%.Safe‑haven assets rallied as well: gold rose more than 2% to $4,812 per ounce, and cryptocurrencies recovered, with Bitcoin up 2.9% to $71,327 and Ether gaining 5.6% to $2,234.Market strategists emphasized the provisional nature of the relief. Jim Reid, Deutsche Bank markets strategist, warned that “investors will be breathing a big sigh of relief, but the durability of the ceasefire remains the key risk.” He noted ongoing Israeli‑Iran strikes and unclear extensions to Lebanon could reignite volatility.Energy analyst Saul Kavonic (MST Financial) described the pause as “an off‑ramp for Trump’s bombastic ultimatum, but not yet an off‑ramp for oil markets or the war.” He expects a limited release of tankers from Hormuz in May, which would ease storage pressure without boosting production.Capital Economics chief economist Neil Shearing highlighted potential transit fees for Hormuz passage, estimating a $1‑2 million charge per tanker—equivalent to roughly $1 per barrel—would have a modest effect on global oil prices but could signal a de‑facto partial nationalisation of the route.TD Securities senior strategist Prashant Newnaha cautioned that “renewed escalation cannot be ruled out, but markets are treating this ceasefire as the real deal, and all parties will sell it as a major win.” He added that oil prices are unlikely to revert to pre‑war levels, keeping inflationary pressures alive.Earlier in the week, U.S. equities swung sharply, with the S&P; 500 dipping 1.2% before rebounding after Pakistan’s prime minister urged Trump to extend the deadline and keep the strait open.The conflict, which began after the U.S. and Israel struck Iranian targets in late February, has choked the Strait of Hormuz—through which about 20% of global oil and LNG supplies flow—fueling a worldwide energy crunch.

Glass Lewis, a leading proxy adviser, has advised investors to vote against BP's chair Albert Manifold because the board chose to exclude a climate‑strategy resolution from the upcoming annual general meeting.The resolution, put forward by activist shareholder group Follow This, sought a discussion of BP's long‑term strategy under scenarios of declining oil and gas demand.BP, currently pivoting back to oil and gas after a faltering renewable push, appointed Manifold in October with a promise to help the company “reach its full potential”.In a parallel leadership change, the firm named Meg O’Neill, a former ExxonMobil executive, as chief executive – making her the first woman to lead BP and its fourth CEO since 2023.Glass Lewis argued that the board’s decision to drop the climate proposal raises serious questions about transparency, shareholder communication and responsiveness, according to a note first reported by Reuters.Manifold responded on BP’s website, stating that the board concluded the Follow This proposal was invalid and would be ineffective if passed.Another proxy adviser, ISS, also recommended voting against BP’s request to retire two older climate‑impact reporting resolutions, contending that the proposals remain relevant despite newer reporting frameworks.Follow This disclosed that 12 institutional investors plan to oppose BP’s move to scrap its climate disclosures, and its CEO Mark van Baal warned that more than 25% of shareholders could vote against the resolution, enough to block it.O’Neill, addressing staff, highlighted the “significant complexity” of today’s environment – geopolitical tension, rapid technological change, and shifting global energy demand – and reaffirmed BP’s mission to deliver energy safely, reliably and efficiently.

The U.S. Supreme Court issued a decision on Monday that removes a procedural obstacle, allowing the Justice Department to proceed with a motion to dismiss the criminal case against Steve Bannon. The case stems from a 2022 conviction on two counts of contempt of Congress for refusing to comply with a subpoena issued by the House committee investigating the January 6, 2021 Capitol attack. Bannon, a former chief strategist for President Donald Trump, served a four‑month prison term after the conviction. Although the sentence is now complete, the Justice Department argues that dismissing the case is "in the interests of justice" and has asked the high court to overturn the lower‑court ruling that kept the conviction in place. Attorney Evan Corcoran, representing Bannon, welcomed the development, stating, "It has been one battle after another for five years, but today the Supreme Court vacated an unjust conviction, reaffirming that politics and prosecution don’t mix." A dismissal would expunge Bannon’s conviction from the record, but the practical impact is minimal because he has already completed his sentence. The move is part of a broader pattern of the Justice Department taking actions that benefit allies of the former president since his return to office in 2024. Background: Bannon, now 72, was a key adviser to Trump’s 2016 campaign and served as the White House’s chief strategist in 2017. After a brief fallout, he reconciled with Trump and was released from Danbury federal prison a week before Trump’s victory over Kamala Harris in the 2024 presidential election. Upon release, Bannon declared himself “far from broken” and resumed hosting his "War Room" podcast, continuing to promote the “America First” brand of right‑wing populism. Legal arguments raised by Bannon’s team centered on claims of executive privilege and challenges to the congressional committee’s authority to issue the subpoena. The case unfolds against a backdrop of numerous pardons granted by Trump to individuals convicted in connection with the Capitol riot and other allies facing charges related to attempts to overturn the 2020 election.

A United States federal judge has rejected a motion from the Department of Justice to reconsider his earlier ruling dismissing subpoenas against Jerome Powell, the chairman of the Federal Reserve.In a six-page opinion published on Friday, Judge James Boasberg reaffirmed his decision to nullify the subpoenas, stating that they were issued for an 'improper purpose': to pressure Powell into compliance with President Donald Trump's demands.The subpoenas were part of an investigation into Powell's handling of renovations to the Federal Reserve's historic buildings in Washington, DC, which have gone over budget. The Trump administration has accused Powell of 'malfeasance' and called for his premature resignation.Boasberg criticized the Trump administration's efforts, saying they presented 'no evidence whatsoever of fraud' and that the subpoenas were an attempt to undermine the Federal Reserve's independence.The ruling is likely to set the stage for the Trump administration to appeal, with US Attorney Jeanine Pirro previously denying any political motivation for the investigation.

Peptides are short chains of amino acids that naturally occur in the body, acting as hormones such as insulin, oxytocin and vasopressin, or as fragments released during protein digestion.In recent years, a wave of interest has turned these molecules into purported therapeutic agents for everything from weight loss to anti‑ageing and tissue repair. Prescription drugs like semaglutide (Wegovy) and tirzepatide (Mounjaro) are synthetic peptides that have undergone rigorous clinical testing and are approved for specific medical uses.However, a large portion of the market consists of unregulated, experimental peptides sold for self‑administration. These products often bypass the strict approval processes required for medicines, raising serious safety concerns.Who is using these products? Initially confined to a niche of powerlifters and bodybuilders in the 2010s, the audience has expanded dramatically. Influential figures such as podcaster Joe Rogan have promoted combinations like the “Wolverine stack” (BPC‑157 and TB‑500) for injury recovery, while other compounds—CJC‑1295, MK‑677, ipamorelin, and GHK‑Cu—are marketed for muscle growth and anti‑ageing. Social media platforms are now flooded with instructions on purchasing and injecting these substances.Scientific backing is scant. Reviews of the literature reveal that most experimental peptides have only been tested in animal or cell models. For example, BPC‑157 shows promise for tendon and muscle repair in pre‑clinical studies, but no randomized human trials have validated these effects. Similarly, TB‑4 and its synthetic analogue TB‑500 have demonstrated limited blood‑vessel formation in laboratory settings, yet human data are absent and both are listed as prohibited substances by the World Anti‑Doping Agency.Researchers also highlight a critical knowledge gap: dosage, frequency and treatment duration remain undefined, making self‑administration a gamble.Legal landscape in the UK is clear that peptides not classified as medicines fall outside the Medicines and Healthcare products Regulatory Agency’s (MHRA) remit. If a seller makes medicinal claims, the product must hold a marketing authorisation under the Human Medicines Regulations 2012. The MHRA warns that labeling items as “research use only” does not shield vendors from enforcement when evidence shows the products are intended for human consumption.Health risks are multi‑fold. Experts caution that benefits observed in animal studies do not guarantee safety in humans. Contamination with harmful impurities or bacterial endotoxins can trigger severe reactions, including septic shock. Injecting excess natural peptides may disrupt the body’s tightly regulated hormonal balance, potentially affecting multiple physiological pathways.There is also theoretical concern that augmenting peptide levels could accelerate tumour growth, as some cancers over‑express certain peptide pathways. While no direct cases have been documented, the possibility underscores the need for caution.Additional dangers include improper injection techniques (e.g., air embolism), unknown interactions with existing medications, and the lack of systematic monitoring of long‑term effects. As one researcher put it, “If something goes wrong, users may never notice until irreversible damage has occurred.”

The UK medicines regulator has opened an inquiry into a growing number of clinics that sell injectable peptides while promoting them as cures for everything from ageing to injury recovery. The investigation, disclosed by the Guardian, focuses on whether these businesses are breaching the Human Medicines Regulations 2012 by making unauthorised medicinal claims. Interest in peptide‑based treatments has surged in recent years, driven by social‑media influencers, some healthcare professionals, and direct‑to‑consumer marketers. Yet the scientific foundation for most of these claims is weak, with the bulk of research confined to animal models or cell‑culture studies. According to an MHRA spokesperson, any clinic that advertises a peptide as having therapeutic benefits must treat the product as a medicine, which triggers a comprehensive regulatory framework. "If clinics offering peptide injections make medicinal claims for those treatments, the products will be considered medicines and subject to regulation," the agency warned, adding that it will act against any identified breaches. Guardian reporters identified several high‑ranking Google search results that list peptides such as Cortexin (promoted for neuroprotection), BPC‑157 (claimed to aid tissue repair), and Thymosin Alpha (advertised to boost immunity). After being contacted, one clinic removed the statements from its website. Another clinic, while acknowledging the limited human evidence, continued to market seven specific peptides, providing price lists (£350 per month for a single peptide, £450 for two) and offering delivery via vials, syringes, or pre‑filled pens for an additional fee. During a free consultation, a clinician highlighted the experimental nature of the products, noting the absence of large‑scale, randomised clinical trials and recommending a break of four to eight weeks between treatment cycles to mitigate unknown risks. The clinician suggested BPC‑157 for post‑exercise recovery, describing it as a facilitator of cellular repair and blood flow, but warned against its use in smokers or individuals with a family history of cancer due to potential angiogenic effects. The second peptide discussed was MOTS‑C, portrayed as a mitochondrial enhancer that could improve stress resilience, lower insulin resistance, and reduce visceral fat by boosting cellular energy production (ATP). The MHRA confirmed it is reviewing whether the clinician’s statements constitute medicinal claims. The clinic defended its approach, emphasizing that it clearly informs clients that the peptides are not licensed medicines and that the evidence base is largely pre‑clinical. In a broader statement, Lynda Scammell, head of borderline products at the MHRA, explained that peptide products may be marketed as cosmetics, supplements, or medicines, and each case is assessed on its intended use, pharmacological effect, and supporting evidence. She added, "We disregard claims that products are for ‘research purposes’ if it is clear that such claims are being used as an attempt to avoid medicines regulations." Peptides are short chains of amino acids, some of which occur naturally (e.g., insulin). While synthetic peptide analogues like semaglutide and tirzepatide have secured approval for weight‑loss treatments, many of the compounds promoted by these clinics remain experimental and lack the rigorous safety and efficacy testing required for medicinal products.

President Donald Trump announced on Truth Social that Pam Bondi is being removed as Attorney General, ending a contentious 14‑month stint at the Justice Department. Bondi, who described her upcoming shift to the private sector as a "transition," will leave the post within the next month. In a rapid reshuffle, Trump elevated Deputy Attorney General Todd Blanche—who previously served as the former president’s criminal‑defense lawyer—to acting attorney general. The president also hinted that EPA Administrator Lee Zeldin could become the permanent replacement, signaling a continued preference for close allies in key legal roles. Bondi’s ouster follows a series of high‑profile controversies. Most notably, her management of the Jeffrey Epstein files drew intense scrutiny. After promising full transparency, the Justice Department released heavily redacted documents that failed to satisfy public and congressional demands for a "client list" and other evidence. Critics, including victims’ attorney Gloria Allred, called her departure "long overdue" for mishandling the files. Beyond the Epstein saga, Bondi struggled to deliver the political prosecutions Trump expected. Efforts to pursue former FBI Director James Comey and other officials linked to investigations of the president stalled or collapsed, fueling Trump’s frustration that she was not "weaponising" the department aggressively enough against his perceived enemies. Bondi, a former Florida attorney general and the state’s first female AG, built a reputation on tough‑on‑crime initiatives such as combating human trafficking and cracking down on "pill mills." However, her limited involvement in the original Epstein non‑prosecution deal and her heated exchange with a Democratic lawmaker—where she called him a "washed‑up loser"—further eroded confidence in her leadership. The White House confirmed that Bondi’s private‑sector role will be announced "in the near future," while Blanche issued a statement on X thanking Trump for the trust placed in him and pledging to "continue backing the blue, enforcing the law, and keeping America safe." Congressional oversight intensifies as the House Oversight Committee had scheduled Bondi to appear before it on April 14 to answer questions about the Epstein documents. With her exit, committee chair James Comer said Republicans would deliberate whether to pursue the subpoena, while Democrats, led by Robert Garcia, insist she "will not escape accountability." Reactions span the political spectrum: Democrats such as Senator Elizabeth Warren denounced the DOJ under Bondi as a "cesspool of corruption," whereas Republican Senator Chuck Grassley praised her responsiveness to oversight and noted a decline in violent crime during her tenure. Republican Thomas Massie urged the next AG to release all Epstein files and pursue arrests. As the administration searches for a permanent attorney general, the choice between Blanche and Zeldin will signal how closely Trump intends to align the Justice Department with his political agenda moving forward.

US President Donald Trump has announced the dismissal of Pam Bondi as US Attorney General, marking his second major cabinet-level shake-up in less than a month. The decision comes amid controversy surrounding Bondi's handling of investigative files related to financier and convicted sex offender Jeffrey Epstein.Trump confirmed the decision on Truth Social, stating that Bondi would be transitioning to a new role in the private sector. He praised Bondi, a longtime supporter, for her service during a period of decreasing violent crime in the US. Deputy Attorney General Todd Blanche will temporarily replace Bondi.The move has raised concerns about the politicization of the Department of Justice, particularly given Bondi's close alignment with Trump's agenda. Critics argue that this has led to politically motivated prosecutions, including investigations into Trump's opponents. Bondi had also faced criticism for her handling of the Epstein files, with lawmakers accusing her of withholding documents.Trump's decision comes as the Department of Justice faces scrutiny over its independence and handling of high-profile cases. The firing has sparked reactions from Democrats, who have called for Bondi to be held accountable for her actions. Shontel Brown, a US Representative, stated that Bondi remains legally obligated to adhere to a subpoena from the House Oversight Committee, which continues to investigate Epstein.